By performing a detailed histological and molecular characterization of the tumor states following NR2F2 genetic gain and loss of functions studies during tumor progression, the authors unravel the molecular mechanisms by which NR2F2 regulates malignant tumor progression, and tumor growth. NR2F2 promotes tumor cell proliferation, and invasive features, while repressing cell death, tumor differentiation and immune cell infiltration of the tumor.
“One of the most remarkable findings of this study is the demonstration that inactivation of NR2F2 promotes tumor differentiation, leading to tumor regression. Despite the spectacular efficacity of pro-differentiation therapy for the treatment of pro-myelomonocytic leukemia, very few pro-differentiation therapies are currently used to treat solid cancers. The development of NR2F2 inhibitors should keep in check many essential cancer functions and is thus a very promising strategy for the development of novel anticancer therapy,”, comments Pr Cedric Blanpain, the senior author of this study.
Cdric Blanpain, together with ULB, and private and public investors founded a company called ChromaCure to discover and develop first-in-class small molecule therapeutics targeting NR2F2 for unmet clinical needs in oncology.
Source: Eurekalert
